Form 4: Omeros Corp Director Hood Receives Stock Option Award

Director Leroy E. Hood receives a stock option to purchase 15,000 shares of Omeros Corp common stock as part of the company's non-employee director compensation policy.

Summary

• Leroy E. Hood, a director of Omeros Corp, was granted a stock option to purchase 15,000 shares of common stock on June 6, 2024.
• The grant is part of Omeros Corporation's non-employee director compensation policy.
• The option was awarded in conjunction with the annual meeting of shareholders held on June 6, 2024.
• The exercise price of the stock option is $3.91.
• The option will fully vest and become exercisable on the day before the date of the 2025 annual meeting of shareholders, contingent on continued service as a director.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock option.

Industry Context

Stock option grants are a common form of compensation for non-employee directors, aligning their interests with the long-term performance of the company. This practice is widespread across the biotechnology industry.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice in the biotechnology industry.
• The size of the grant (15,000 shares) is within the typical range for companies of Omeros' size and market capitalization.
• Comparable companies such as BioCryst Pharmaceuticals and Horizon Therapeutics also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders: The grant aligns director interests with shareholder value.
• Employees: The grant is part of a broader compensation strategy.

Key Dates